How many drugs treat Nosocomial pneumonia?

Drug Landscape tracks 10 marketed treatments for Nosocomial pneumonia (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/nosocomial-pneumonia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Nosocomial pneumonia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nosocomial pneumonia (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Nosocomial pneumonia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Zerbaxa	CEFTOLOZANE	Cubist Pharms	Cephalosporin Antibacterial		2014-01-01
Zosyn	TAZOBACTAM	Merck Sharp & Dohme B.V.	beta Lactamase Inhibitor		1993-01-01
Cipro	ciprofloxacin	Bayer AG	Fluoroquinolone antibiotic	DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A	1987-10-22
Arikayce Kit	AMIKACIN	Bristol-Myers Squibb	Aminoglycoside Antibacterial		1981-01-01
Piperacillin And Tazobactam	Piperacillin Sodium	Pfizer	Penicillin-class antibacterial with beta-lactamase inhibitor	Bacterial cell wall; beta-lactamase enzyme	1981-01-01
Vantobra	Tobramycin Sulfate	Pfizer	tobramycin	Taste receptor type 2 member 20	1974-01-01
Tobi	tobramycin	Novartis		Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)
Ofloxacine	Ofloxacine	Assistance Publique - Hôpitaux de Paris		Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1
Nebcin	Nebcin	University Hospital, Lille		Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)
Ciprofloxacine	Ciprofloxacine	Poitiers University Hospital		DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 4 drugs in Nosocomial pneumonia
Pfizer · 2 drugs in Nosocomial pneumonia
Bayer AG · 1 drug in Nosocomial pneumonia
Bristol-Myers Squibb · 1 drug in Nosocomial pneumonia
Cubist Pharms · 1 drug in Nosocomial pneumonia
Merck Sharp & Dohme B.V. · 1 drug in Nosocomial pneumonia
Novartis · 1 drug in Nosocomial pneumonia
Poitiers University Hospital · 1 drug in Nosocomial pneumonia
University Hospital, Lille · 1 drug in Nosocomial pneumonia
Assistance Publique - Hôpitaux de Paris · 1 drug in Nosocomial pneumonia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Nosocomial pneumonia:

Cite this brief

Drug Landscape (2026). Nosocomial pneumonia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/nosocomial-pneumonia. Accessed 2026-06-10.

Nosocomial pneumonia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing